SEC For	rm 4 FORM	4	UNITE) STA	TES	5 SI	ECUR	ITIE	ES AND	E	КСНА	NGE C	омм	ISSION					
					Washington, D.C. 20549											OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See						A pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940											OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		
1. Name and Address of Reporting Person [*] <u>HARRIGAN EDMUND</u> (Last) (First) (Middle)					<u>Ph</u> 3. C	Date of	Bio Ph	arm	ker or Tradii aceutica saction (Mor	ls I	<u>nc</u> [PH	(Cł	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify below) below)						
C/O PHASEBIO PHARMACEUTICALS, INC. 1 GREAT VALLEY PARKWAY, SUITE 30						05/19/20224. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
(Street) MALVERN PA 19355						Line) X Form file									led by One Reporting Person led by More than One Reporting				
(City) (State) (Zip)																			
			ole I - Nor						· · ·	Disp				ly Owned					
1. Title of Security (Instr. 3) Date (Month/Date)						ar)	2A. Deem Execution if any (Month/Da	Date,	Transaction Dispose Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 a		Benefici Owned I	ies Forn cially (D) o Following (I) (Ir ed ction(s)		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	nt (A) or Pi (D) Pi				Reporte Transac (Instr. 3	(instr. 4)	
			Table II -						uired, Di , options					v Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares						
Non- employee Director Stock Option (right to buy)	\$0.8419	05/19/2022			A		17,500		(1)	05	5/18/2032	Common Stock	17,500	\$0	17,500)	D		
Restricted Stock Units	(2)	05/19/2022			Α		3,750		(3)		(3)	Common Stock	3,750	\$0	3,750		D		

Explanation of Responses:

1. The shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date.

2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.

3. The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date.

Remarks:

/s/ John P. Sharp, Attorney-infact 05/20/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.